Alkermes CMO Buys 5,000 Shares at Record Low, Betting on Breakthrough Therapy Boom
Alkermes insider buys 5,000 shares at $19.34 under a 10‑b‑plan, betting on a short‑term rise as the company’s Breakthrough Therapy for alixorexton gains momentum.
3 minutes to read